In simple words: This code is for a medicine called BCG, given directly into the bladder to treat bladder cancer.The doctor puts it in through a thin tube.The amount is measured in milligrams (mg), and the code is for each mg of medicine used.

This HCPCS code represents the intravesical instillation of 1 mg of live Bacillus Calmette-Guérin (BCG).BCG is a live attenuated strain of Mycobacterium bovis used in immunotherapy for bladder cancer. The code is reported for each milligram of BCG instilled.Dosage and administration vary depending on the specific clinical scenario and the brand of BCG used (e.g., TheraCys®, TICE®),typically involving weekly instillations for six weeks initially, followed by maintenance therapy at varying intervals.The instillation is administered via catheter into an emptied bladder, and the patient maintains specific positions to ensure thorough distribution of the BCG throughout the bladder.This code represents the supply of the drug; separate codes may apply for administration.

Example 1: A 65-year-old male patient presents with a diagnosis of superficial bladder cancer (Ta, T1). Following a transurethral resection of bladder tumor (TURBT), the urologist prescribes a course of intravesical BCG therapy.The patient receives six weekly instillations of 50mg BCG (J9030 x 50 units per instillation) followed by maintenance instillations as determined by the physician., A 72-year-old female patient with carcinoma in situ (CIS) of the bladder undergoes intravesical BCG instillation. Due to BCG shortage, the physician prescribes a lower dose (e.g., 25 mg per treatment). J9030 is reported with 25 units per treatment. Careful documentation of the reduced dose and clinical justification is crucial for appropriate reimbursement., A patient with recurrent superficial bladder cancer receives multiple cycles of intravesical BCG, each consisting of a varying dose (e.g., 30 mg, 40 mg, then 50 mg). Each instillation requires appropriate unit reporting of J9030 reflecting the actual dosage.

* Diagnosis of bladder cancer (ICD-10 code).* Pathology report confirming the type and stage of the cancer.* Documentation of the number of milligrams of BCG instilled per treatment.* Procedure notes detailing the administration of the BCG, including the method of instillation, and any complications.* Physician's order specifying the dosage and treatment schedule.* Progress notes documenting the patient's response to treatment and any adverse events.

** Brand names for BCG include TheraCys® and TICE®.The recommended dose and administration instructions vary depending on the brand and the clinical scenario.Always refer to the specific product package insert and clinical guidelines for complete information.This code only represents the supply of the drug and separate codes may be required for administration.Thorough documentation is required to justify medical necessity and support accurate coding.